PLUS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.16 USD | -3.57% |
|
+20.00% | +23.42% |
| 05-09 | Transcript : Plus Therapeutics, Inc. - Special Call | |
| 05-09 | Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC | CI |
Chart calendar Plus Therapeutics, Inc.
bbbab8fb9cc205f18.8DAvzK4fOY8hYYocyGQdOH6NY2SzVN4QCwFE_F46j2w.nEEXgOhnW_5UDeZepzVfagT1KSqeYOdaW1IdsWtd-BSUCXmdll1I1ksryw~3136c36b8e441a7151e7434e92f12c6b
Upcoming events on Plus Therapeutics, Inc.
Past events on Plus Therapeutics, Inc.
| 09/05/2024 13:30 | Business Update Call |
| 17/04/2024 | Q1 2024 Earnings Release (Projected) |
| 05/04/2024 12:30 | National Comprehensive Cancer Network Conference |
| 19/03/2024 | Benzinga Virtual Healthcare Summit |
| 11/03/2024 | Investor Meeting - JonesTrading |
| 05/03/2024 22:00 | Q4 2023 Earnings Call |
| 05/03/2024 21:05 | Q4 2023 Earnings Release |
| 06/12/2023 12:00 | Targeted Radiopharmaceuticals Summit |
| 04/12/2023 | San Antonio Breast Cancer Symposium |
| 20/11/2023 15:00 | Investor Meeting - Key Opinion Leader |
| 19/11/2023 01:05 | Society for Neuro Oncology Meeting - Multi-parametric MRI and SPECT Assessment of Treatment Dose and |
| 18/11/2023 03:30 | Society for Neuro Oncology Meeting - Update Report of the ReSPECT-GBM Phase I/IIa Dose Escalation Tr |
| 15/11/2023 | Society for Neuro Oncology Meeting |
| 31/10/2023 21:00 | Q3 2023 Earnings Call |
| 31/10/2023 20:05 | Q3 2023 Earnings Release |
| 19/10/2023 17:30 | ThinkEquity Conference |
| 16/10/2023 | Bio Investor Forum |
| 08/10/2023 | JonesTrading Healthcare Summit |
| 03/10/2023 12:00 | Innovations in Cancer Prevention and Research Conference |
| 20/09/2023 | SNMMI Fall Therapeutics Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 7,00 6,50 7.66% | 0,30 0,30 0.25% | 0,00 0,00 - | 0,22 0,72 -68.72% | 4,91 4,45 10.39% | 5,08 |
|
EBITDA Million USD | Released Forecast Spread | -2,76 -9,60 71.24% | -8,44 -6,70 -25.93% | -11,8 -10,9 -8.69% | -19,1 -15,6 -22.39% | -12,7 -11,4 -11.34% | -10,0 |
|
EBIT Million USD | Released Forecast Spread | -3,66 -11,3 67.64% | -9,58 -8,01 -19.61% | -12,5 -12,1 -3.61% | -19,7 -18,6 -6.05% | -13,3 -13,8 3.72% | -21,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -10,9 -14,2 23.33% | -8,24 -6,50 -26.74% | -13,4 -12,8 -4.3% | -20,3 -19,1 -5.95% | -13,3 -13,9 4.11% | -21,6 |
|
Net income Million USD | Released Forecast Spread | -11,4 -14,8 22.7% | -8,24 -6,64 -24.06% | -13,4 -12,8 -4.3% | -20,3 -19,1 -5.95% | -13,3 -13,9 4.11% | -21,6 |
|
EPS USD | Released Forecast Spread | 0,00 0,00 - | -27,9 -22,6 -23.18% | -16,6 -16,4 -1.22% | -11,5 -11,2 -3.13% | -4,24 -4,87 12.88% | -2,41 |
| Announcement Date | 30/03/20 | 22/02/21 | 24/02/22 | 23/02/23 | 05/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,07 0,00 - | 0,15 0,66 -77.06% | 0,51 0,43 16.77% | 1,85 0,75 146.22% | 1,24 1,16 7.11% | 1,31 0,85 54.35% | 1,69 | 1,69 | 1,75 | 2,50 | 1,65 |
|
EBITDA Million USD | Released Forecast Spread | -3,58 -3,00 -19.27% | -3,78 -3,30 -14.52% | -4,97 -3,40 -46.03% | -4,94 -3,80 -29.89% | -5,41 -2,40 -125.54% | -4,42 -3,70 -19.51% | -1,33 -3,20 58.44% | -2,94 -2,80 -5.14% | -3,71 -2,90 -27.9% | -2,50 | -2,50 | -2,50 | -2,50 | -2,70 |
|
EBIT Million USD | Released Forecast Spread | -3,96 -3,50 -13.05% | -3,93 -4,10 4.24% | -5,12 -4,14 -23.82% | -5,09 -4,81 -5.96% | -5,57 -4,44 -25.57% | -4,72 -5,31 11.08% | -1,49 -4,77 68.74% | -3,25 -3,18 -2.14% | -3,86 -4,01 3.8% | -4,95 | -5,00 | -5,00 | -4,30 | -5,67 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -4,16 -3,62 -14.67% | -4,12 -4,30 4.28% | -5,28 -4,23 -24.91% | -5,22 -4,90 -6.54% | -5,66 -4,52 -25.06% | -4,81 -5,36 10.32% | -1,48 -4,82 69.23% | -3,22 -3,20 -0.69% | -3,81 -4,02 5.3% | -4,95 | -5,00 | -5,00 | -4,30 | -5,67 |
|
Net income Million USD | Released Forecast Spread | -4,16 -3,62 -14.67% | -4,12 -4,30 4.28% | -5,28 -4,23 -24.91% | -5,22 -4,90 -6.54% | -5,66 -4,52 -25.06% | -4,81 -5,36 10.32% | -1,48 -4,82 69.23% | -3,22 -3,20 -0.69% | -3,81 -4,02 5.3% | -4,95 | -5,00 | -5,00 | -4,30 | -5,67 |
|
EPS USD | Released Forecast Spread | -3,75 -3,90 3.85% | -2,85 -2,70 -5.56% | -3,60 -3,25 -10.77% | -2,85 -3,20 10.94% | -2,40 -2,20 -9.09% | -2,10 -2,20 4.55% | -0,59 -2,03 70.94% | -1,00 -1,18 15.01% | -0,70 -1,17 40.34% | -1,09 | -0,75 | -0,61 | -0,56 | -0,66 |
| Announcement Date | 24/02/22 | 21/04/22 | 21/07/22 | 20/10/22 | 23/02/23 | 20/04/23 | 14/08/23 | 31/10/23 | 05/03/24 | - | - | - | - | - |
More events
Past sector events for Plus Therapeutics, Inc.
| 10/05/2024 12:00 | HUMACYTE, INC.: Q1 2024 Earnings Release |
| 09/05/2024 | NOVAVAX, INC.: Q1 2024 Earnings Release |
| 09/05/2024 | TAKARA BIO INC.: Q4 2023 Earnings Release |
| 09/05/2024 | CHABIOTECH CO.,LTD.: Q1 2024 Earnings Release (Projected) |
| 09/05/2024 21:10 | GYRE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 09/05/2024 21:05 | ARS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 09/05/2024 21:05 | HILLEVAX, INC.: Q1 2024 Earnings Release |
| 09/05/2024 21:05 | BIOHAVEN LTD.: Q1 2024 Earnings Release |
| 09/05/2024 21:05 | OMNIAB, INC.: Q1 2024 Earnings Release |
| 09/05/2024 21:05 | 4D MOLECULAR THERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PSTV Stock
- Calendar Plus Therapeutics, Inc.
